Opinion|Videos|February 5, 2025
Genetic Testing and Molecular Profiling in AML
Panelists discuss the importance of genetic testing, particularly for KMT2A and NPM1 mutations, in identifying patients who would benefit from revumenib, the role of molecular profiling in identifying high-risk acute monocytic leukemia (AML) patients, approaches to KMT2A testing, and when to recommend RNA over DNA testing, along with guidance for institutions lacking standardized diagnostic testing protocols.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. LeBlanc to ask Dr. Goldberg: Highlight the importance of genetic testing, specifically KMT2A and NPM1, in identifying patients who would benefit from revumenib.
- Dr. LeBlanc to ask Dr. Blachly: Briefly comment on the role of molecular profiling in identifying high-risk patients with AML.
- Dr. LeBlanc to ask Dr. 4: How do you approach KMT2A testing and when would you recommend RNA over DNA testing? And why?
- What guidance would you offer to institutions that do not yet have standardized diagnostic testing protocols?
- Dr. LeBlanc to ask Dr. 4: How do you approach KMT2A testing and when would you recommend RNA over DNA testing? And why?
Advertisement
Related to this article
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
A gene expression test identified the first 3 years after childbirth as a potential window of higher biological risk in breast cancer.
A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.
Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.
An MD Anderson Cancer Center study identified a new link between immune cells and a copper-induced form of cell death called cuproptosis.
Early phase 2 data showed a median OS of 29.3 months with BPM31510 plus chemoradiation in an MGMT-unmethylated subgroup of treatment-naive glioblastoma.
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer
2
CAR T-Cell Engineering Produces Early Efficacy Signals in Glioblastoma
3
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
4
International Intel: A Glance at the Top Global Breast Cancer News From April-June 2026
5